175 related articles for article (PubMed ID: 33316404)
1. Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold.
Kinzel O; Steeneck C; Anderhub S; Hornberger M; Pinto S; Morschhaeuser B; Albers M; Sonnek C; Wang Y; Mallinger A; Czekańska M; Hoffmann T
Bioorg Med Chem Lett; 2021 Feb; 33():127738. PubMed ID: 33316404
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors.
Steeneck C; Kinzel O; Anderhub S; Hornberger M; Pinto S; Morschhaeuser B; Albers M; Sonnek C; Czekańska M; Hoffmann T
Bioorg Med Chem Lett; 2021 Feb; 33():127744. PubMed ID: 33333163
[TBL] [Abstract][Full Text] [Related]
3. Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.
Hamilton MM; Mseeh F; McAfoos TJ; Leonard PG; Reyna NJ; Harris AL; Xu A; Han M; Soth MJ; Czako B; Theroff JP; Mandal PK; Burke JP; Virgin-Downey B; Petrocchi A; Pfaffinger D; Rogers NE; Parker CA; Yu SS; Jiang Y; Krapp S; Lammens A; Trevitt G; Tremblay MR; Mikule K; Wilcoxen K; Cross JB; Jones P; Marszalek JR; Lewis RT
J Med Chem; 2021 Aug; 64(15):11302-11329. PubMed ID: 34292726
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor.
Wu Y; Duan Q; Zou Y; Zhu Q; Xu Y
Bioorg Med Chem Lett; 2021 Nov; 52():128373. PubMed ID: 34560264
[TBL] [Abstract][Full Text] [Related]
5. Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.
Weng T; Qiu X; Wang J; Li Z; Bian J
Eur J Med Chem; 2018 Jan; 143():656-669. PubMed ID: 29220788
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors.
Pan L; Zheng Q; Chen Y; Yang R; Yang Y; Li Z; Meng X
Eur J Med Chem; 2018 Sep; 157():423-436. PubMed ID: 30103191
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays.
Ge H; Mao L; Zhao J; Wang Y; Shi D; Yang X; Wang X; Liu H; Yao X
J Comput Aided Mol Des; 2021 May; 35(5):679-694. PubMed ID: 33905074
[TBL] [Abstract][Full Text] [Related]
9. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
Fung SP; Wang H; Tomek P; Squire CJ; Flanagan JU; Palmer BD; Bridewell DJ; Tijono SM; Jamie JF; Ching LM
Bioorg Med Chem; 2013 Dec; 21(24):7595-603. PubMed ID: 24262887
[TBL] [Abstract][Full Text] [Related]
11. Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.
Gao D; Li Y
Bioorg Med Chem; 2017 Jul; 25(14):3780-3791. PubMed ID: 28526475
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor.
Balog A; Lin TA; Maley D; Gullo-Brown J; Kandoussi EH; Zeng J; Hunt JT
Mol Cancer Ther; 2021 Mar; 20(3):467-476. PubMed ID: 33298590
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent IDO1 inhibitors derived from tryptophan using scaffold-hopping and structure-based design approaches.
Zou Y; Wang Y; Wang F; Luo M; Li Y; Liu W; Huang Z; Zhang Y; Guo W; Xu Q; Lai Y
Eur J Med Chem; 2017 Sep; 138():199-211. PubMed ID: 28667875
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 5-(N-hydroxycarbamimidoyl) benzofuran derivatives as novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Jung J; Yoon H; Sohn TI; Jang K; Yoo Y; Jeong I; Shin JE; Lee JH; Ann J; Lee J
Bioorg Med Chem Lett; 2021 May; 40():127963. PubMed ID: 33741464
[TBL] [Abstract][Full Text] [Related]
15. Taking advantage of the interaction between the sulfoxide and heme cofactor to develop indoleamine 2, 3-dioxygenase 1 inhibitors.
Wang Y; Jia S; Chen Y; Liao X; Jie R; Jiang L; Wang T; Wen H; Gan W; Cui H
Bioorg Chem; 2024 Jul; 148():107426. PubMed ID: 38733750
[TBL] [Abstract][Full Text] [Related]
16. A Novel High Throughput Virtual Screening Protocol to Discover New Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Xu H; Song Y; Yang Q
Chem Pharm Bull (Tokyo); 2017; 65(8):714-717. PubMed ID: 28768924
[TBL] [Abstract][Full Text] [Related]
17. A Series of 2-((1-Phenyl-1H-imidazol-5-yl)methyl)-1H-indoles as Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Zheng Y; Stafford PM; Stover KR; Mohan DC; Gupta M; Keske EC; Schiavini P; Villar L; Wu F; Kreft A; Thomas K; Raaphorst E; Pasangulapati JP; Alla SR; Sharma S; Mittapalli RR; Sagamanova I; Johnson SL; Reed MA; Weaver DF
ChemMedChem; 2021 Jul; 16(14):2195-2205. PubMed ID: 33759400
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening.
Guo W; Yao S; Sun P; Yang TB; Tang CP; Zheng MY; Ye Y; Meng LH
Acta Pharmacol Sin; 2020 Mar; 41(3):423-431. PubMed ID: 31197246
[TBL] [Abstract][Full Text] [Related]
19. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
Sari S; Tomek P; Leung E; Reynisson J
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795096
[TBL] [Abstract][Full Text] [Related]
20. Advances in the discovery and development of selective heme-displacing IDO1 inhibitors.
Sun L
Expert Opin Drug Discov; 2020 Oct; 15(10):1223-1232. PubMed ID: 32568559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
